TTD | Drug: D0X4NF

Drug General Information
Drug ID	D0X4NF
Former ID	DIB006451
Drug Name	Radiosensitizer gene therapy
Synonyms	Radiosensitizer gene therapy (prostate cancer)
Indication	Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10:C25]		Phase 3	[550209]
Company	Advantagene
Target and Pathway
Target(s)	Thymidine kinase	Target Info	Inhibitor	[534746]
References
Ref 550209	Clinical pipeline report, company report or official report of Advantagene.
Ref 534746	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.

Drug Information